The biological drug for the treatment of psoriasis, ixekizumab, which is marketed under the name Taltz, is now available in Spain, and was approved to be included in the national health system last December, when clinical trials showed its effectiveness to clear plates presenting patients with moderate to severe psoriasis significantly.
Ixekizumab neutralizing the activity of a cytokine of the immune system involved in the inflammatory process associated with cutaneous lesions and joint characteristics of psoriasis
In studies conducted before approval – involving more than 3,800 patients – was analyzed the degree of lightening of the skin which manages medication, using for this purpose the PASI index that measures the severity and the extent of the injury. After 12 weeks of treatment, there was an improvement in 75% (PASI 75) in 90% of patients, a 70% obtained a 90% improvement (PASI 90), and up to 40% achieved the total clearance of plates (PASI 100).
The follow-up of the patients up to 60 weeks allowed check successful improvements are maintained, and that the toxicity of the drug is similar to that of the others of this type. Ixekizumab is a monoclonal antibody that has been developed to join the interleukin 17A (IL-17A), a cytokine in the immune system that is involved in the inflammatory process associated with cutaneous lesions and joints that characterize psoriasis and, to neutralize the activity of this substance, it decreases inflammation and clear plates.
The drug is administered every 15 days subcutaneously during the 12 weeks of treatment and then once a month, and currently, biomarkers of response are being studied to find out why certain patients achieved significantly higher clearance.